AIM:To study efficacy,safety,administration approaches of pellet of lornoxicam in treating pain caused by moderate and advanced cancers(import clinical verifi cation).METHODS:Multiple center, random,double blind,and self-control method wa s used. Lornoxicam and positive control drug(tramadol) was randomly labeled as A and B.All qualified patients accepted A and B in turn.Purge drugs was given dur ing interval.Number evaluation method was used to assay pain level and changes.E ffective period,optimal relief time,and duration were computed.Level of adverse effects and its relation with drugs were evaluated.RESULTS:32 patients were eval uated including 22 cases of moderate pain and 10 of advanced pain.When approache s of drug administered were stratified,there was no significant difference in ef ficacy between A and B considering single drug titration for drug administration according to need or time. Administration approaches included 2 pellets a time, twice a day(2#BID);1 pellet a time,three times a day(1#TID);1 pellet a time, twice a day(1#BID).When stratification was carried out according to pain severi ty,efficacy of A and B for moderate pain and severe pain varied between 74.2%-92.3%,55.0%-92.6%,respectively.There was no significant difference.Work ti me, optimal relief time,and duration for A and B were about 0.8 hour,1.5 hour,an d 8.2 hour.There was no statistical significance.Incidence of adverse effect for lornoxicam and tramadol was 20.0% and 33.3%,respectively(P< 0.05). Superior ity score for them was 7.6±2.4 and 6.1±2.1,respectivley(P< 0.05).CONCLUSION: Lornoxicam had favorable effect on moderate and severe cancer pain, and is simil ar to drug of second rung such as tramadol. But its adverse reactions are sligh ter and less common compared with tramadol. Patients’ content degree for lornoxi cam is higher than that for tramadol. 2#BID,1#TID,1#BID are more common. Cons idering small sample, its efficacy, therapeutic effect, safety need further inve stigation. AIM: To study efficacy, safety, administration approaches of pellet of lornoxicam in treating pain caused by moderate and advanced cancers (import clinical verifi cation) .METHODS: Multiple center, random, double blind, and self-control method wa s used. Lornoxicam and positive control drug (tramadol) was randomly labeled as A and B. All qualified patients accepted A and B in turn. Population drugs were given dur ing interval. Number evaluation method was used to assay pain level and changes. Efective period, optimal relief time, and duration were computed. Level of adverse effects and its relation with drugs were .RESULTS: 32 patients were eval uated including 22 cases of moderate pain and 10 of advanced pain .When approache s of drug administered were stratified, there was no significant difference in ef ficacy between A and B considering single drug titration for drug administration according to need or time. Administration approaches included 2 pellets a time, twice a day (2 # BID); 1 pellet a time, three times a day (1 # TID); 1 pellet a time, twice a day (1 # BID) .When stratification was carried out according to pain severi ty, efficacy of A and B for moderate pain and severe pain varied between 74.2% -92.3%, 55.0% -92.6%, respectively. There was no significant difference. Work ti me, optimal relief time, and duration for A and B were about 0.8 hour, 1.5 hour, an d 8.2 hour. .Inidence of adverse effect for lornoxicam and tramadol was 20.0% and 33.3%, respectively (P <0.05). Superior ity score for them was 7.6 ± 2.4 and 6.1 ± 2.1, respectivley (P <0.05) .CONCLUSION: Lornoxicam had favorable effect on moderate and severe cancer pain, and is simil ar to drug of second rung such as tramadol. But its adverse reactions are sligh ter and less common compared with tramadol. Patients’ content degree for lornoxi cam is higher than that for tramadol. 2 # BID, 1 # TID, 1 # BID are more common. Cons idering small sample, its efficacy, therapeutic effect, safety need further inve stiga tion.